Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Pediatrix Medical Group, Inc. (NYSE: MD) is a physician-led provider of services for women, babies and children, with specialties in obstetrics, maternal-fetal medicine, neonatology and multiple pediatric subspecialties. News about MD stock frequently centers on its financial performance, portfolio management decisions and clinical leadership in neonatal and pediatric care.
Investors following Pediatrix news will see regular quarterly earnings releases that discuss net revenue, net income, Adjusted EBITDA and Adjusted EPS, along with details on same-unit revenue trends, patient volumes, reimbursement-related factors, payor mix and hospital contract administrative fees. These updates often explain how hospital-based and office-based patient services, particularly neonatology services and neonatal intensive care unit (NICU) days, influence the company’s results.
Pediatrix also issues news on strategic and capital allocation actions, such as the authorization of a share repurchase program of up to a specified dollar amount of its outstanding common stock. Such announcements describe the intended use of the program, its term and the flexibility the company retains to adjust or discontinue repurchases. Board and governance developments, including the appointment of independent directors with extensive pediatric health care experience, are disclosed through press releases and related SEC filings.
Beyond financial and governance updates, Pediatrix highlights its role in research, education and quality improvement. News items include information about NEO: The Conference for Neonatology, a long-running educational meeting that addresses advancements and best practices in neonatal care, and about the activities of the Pediatrix Center for Research, Education, Quality and Safety. Readers who monitor MD news can track how these clinical and educational initiatives align with the company’s hospital-based neonatology and pediatric subspecialty services. For ongoing coverage, this page aggregates company press releases and related market-moving updates.
Pediatrix Medical Group (NYSE: MD) has appointed James D. Swift, M.D., as the new Chief Executive Officer, succeeding Mark S. Ordan, who has transitioned to Executive Chair. This leadership change, effective at year-end, follows Ordan's tenure since July 2020, during which he oversaw significant strategic developments, including a focus on women's and children's care and a strengthening of the company's balance sheet. Dr. Swift has been with Pediatrix since 2009, previously serving as Chief Development Officer and COO.
Summary not available.
Pediatrix Medical Group, Inc. (NYSE:MD) will present at the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 3:15 p.m. PT in Rancho Palos Verdes, California. The presentation will be available via live audio webcast on the company's website. Pediatrix is the leading provider of physician services, focusing on coordinated care for women, infants, and children across various specialties. The company operates with over 4,800 clinicians in 37 states and Puerto Rico.
Pediatrix Medical Group (NYSE: MD) reported Q3 2022 earnings of $0.35 per share, with net revenue of $490 million, down from $492.9 million year-over-year. Adjusted EBITDA was $58 million, reflecting operational challenges in billing and collections, and a decline in reimbursement from commercial payors. Despite these issues, Pediatrix's Adjusted EPS from continuing operations was $0.40. The company anticipates 2022 Adjusted EBITDA will range from $240 million to $245 million, indicating strategic efforts are underway to enhance revenue cycle management.
Pediatrix Medical Group, Inc. (NYSE: MD) will hold an investor conference call on November 3, 2022, at 9:00 a.m. ET to discuss its quarterly operational results for the period ending September 30, 2022. A detailed press release will precede the call, providing insights into the company's financial performance. The call will be accessible via webcast on the company's investor relations page. Pediatrix is a leading provider of physician services focused on pediatrics and obstetrics, serving across 37 states and Puerto Rico.
Pediatrix Medical Group, Inc. (NYSE: MD) commented on the final rule from August 19, 2022, regarding the No Surprises Act. The rule stipulates that the qualifying payment amount (QPA) is one of several factors considered in the independent dispute resolution (IDR) process for out-of-network payment rates. Key factors include provider training, market share, patient acuity, facility status, and good faith negotiations. Pediatrix emphasizes the importance of safeguarding against potential payor manipulation of the QPA and is committed to ensuring compliance with the new rules for the continuity of care.
Pediatrix Medical Group, Inc. (NYSE: MD) reported earnings from continuing operations of $0.36 per share for Q2 2022, with Adjusted EPS of $0.47. The company achieved net revenue of $486 million, a 2.7% increase from the prior year, primarily due to acquisitions. However, same-unit revenue decreased by 1.3%. Operating expenses rose to $330.8 million, reflecting acquisitions. Adjusted EBITDA for Q2 was $66 million. Cash from continuing operations was $81.6 million. The company anticipates 2022 Adjusted EBITDA between $260-$270 million.
Pediatrix Medical Group (NYSE: MD) will host an investor conference call on August 4, 2022, at 9:00 a.m. ET, to discuss its Q2 2022 operational results. A detailed press release will precede the call, issued before market opening on the same day. Pediatrix is a leading provider of physician services, focusing on women, babies, and children through over 4,800 affiliated clinicians across 37 states and Puerto Rico.
For further information, visit www.pediatrix.com/investors.
Mednax, Inc. (NYSE: MD) has announced its corporate name change to Pediatrix Medical Group, Inc., effective July 1, 2022. This rebranding emphasizes its commitment as a premier provider of healthcare services for women, infants, and children. CEO Mark S. Ordan highlighted the significance of returning to the well-respected Pediatrix name. Shareholders are not required to take any action as existing shares will automatically represent the new name. This transition marks a strategic focus on pediatrics and obstetrics, following the company's extensive service history since its inception in 1979.
Mednax, Inc. announces the appointment of James D. Swift, M.D. as Chief Operating Officer and Curtis B. Pickert, M.D. as Chief Physician Executive, emphasizing their commitment to high-quality patient care and operational growth. Both doctors have over a decade of leadership experience within the company. Dr. Swift, previously Executive Vice President and Chief Development Officer, and Dr. Pickert, former Executive Vice President of Clinical Services, aim to enhance Mednax's service delivery across various specialties.